淋巴结因素在预测N1b期甲状腺乳头状癌治疗后复发中的协同作用
本研究纳入2013至2017年接受手术的1067例临床N1b期甲状腺乳头状癌患者,采用Cox回归分析淋巴结因素与复发的关联。多因素分析显示最大径>3 cm、gENE和LNR>0.21与全部位及淋巴结复发相关,LNR与gENE存在交互作用;无gENE患者中LNR与复发相关,有gENE时LNR不再相关。
要点
- 最大径>3 cm、gENE和LNR>0.21是全部位及淋巴结复发的独立危险因素。
- LNR与gENE存在交互作用,全部位复发交互P=.009,淋巴结复发交互P=.02。
- 无gENE患者中LNR与复发相关,有gENE时LNR与复发无显著关联。
核心结论
- 淋巴结因素在预测临床N1b期甲状腺乳头状癌患者复发中具有协同作用。
- 增加淋巴结清扫数量可能仅降低无gENE患者的复发,而对有gENE患者无此作用。
研究设计与样本
- 纳入2013至2017年接受手术的临床N1b期甲状腺乳头状癌患者1067例。
- 采用Cox比例风险回归模型评估淋巴结因素与复发的关联,并根据显著淋巴结因素进行交互和分层分析。
主要发现
- 单因素分析中所有淋巴结因素(双侧转移、最大径>3 cm、mENE、gENE、MLN、LNY和LNR)均与全部位及淋巴结复发显著相关(均P<.05)。
- 多因素分析显示最大径>3 cm与全部位复发HR 2.58(95%CI 1.67-4.00)、淋巴结复发HR 2.63(95%CI 1.67-4.13)相关,均P<.01。
- 多因素分析显示gENE与全部位复发HR 1.87(95%CI 1.26-3.01)、淋巴结复发HR 1.90(95%CI 1.15-3.12)相关,均P<.01。
- 多因素分析显示LNR>0.21与全部位复发HR 1.68(95%CI 1.11-2.42)、淋巴结复发HR 1.76(95%CI 1.17-2.66)相关,均P<.01。
- LNR与gENE存在交互作用(全部位复发交互P=.009;淋巴结复发交互P=.02);无gENE患者中LNR与全部位复发HR 2.41(95%CI 1.50-3.87)、淋巴结复发HR 2.51(95%CI 1.52-4.14)相关,均P<.001;有gENE时LNR与全部位复发HR 0.81(95%CI 0.43-1.54,P=.53)、淋巴结复发HR 0.85(95%CI 0.43-1.67,P=.64)无显著关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nodal factors are important predictors of prognosis for papillary thyroid carcinoma (PTC), but their synergistic effect is not well understood. We aimed to explore their synergy in predicting recurrence of clinical N1b (cN1b) PTC. METHODS: Patients who underwent surgery for cN1b PTC from 2013 to 2017 were enrolled. The association between nodal factors and recurrence was assessed using Cox proportional hazards regression models. Interaction and stratified analyses were conducted according to significant nodal factors. RESULTS: Of 1067 cN1b PTC patients included, all nodal factors (bilateral metastasis, largest dimension > 3 cm, micro and gross extranodal extension (mENE, gENE), number of metastatic lymph nodes [MLN], lymph node yield [LNY], and ratio LNR]) were significantly associated with all site and nodal recurrence in the univariate analysis (all P < .05). Multivariate analyses revealed largest dimension > 3 cm, gENE and LNR > 0.21 were associated with elevated both all site (hazard ratio [HR] [95% CI], 2.58 [1.67-4.00], 1.87 [1.26-3.01], 1.68 [1.11-2.42], all P < .01) and nodal recurrences (HR [95% CI], 2.63 [1.67-4.13], 1.90 [1.15-3.12], 1.76 [1.17-2.66], all P < .01). LNR and gENE had interactive effect (all site recurrence: P for interaction = .009; nodal recurrence: P for interaction = .02). LNR was significantly associated with recurrence in patients without gENE (HR [95% CI], all site recurrence: 2.41 [1.50-3.87]; nodal recurrence: 2.51 [1.52-4.14], all P < .001), while when gENE appeared, LNR was no longer associated with recurrence (HR [95% CI], all site recurrence: 0.81 [0.43-1.54], P = .53; nodal recurrence: 0.85 [0.43-1.67], P = .64). CONCLUSION: Nodal factors have synergistic effect in predicting recurrence in cN1b PTC patients. Increasing lymph nodes harvest may only decrease recurrence in patients without gENE, while not in gENE patients.
引用
- Xian K, Xu S, Huang H, et al. Synergy of Nodal Factors in Predicting Recurrence After Treatment of N1b Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2024. PMID: 38748619. doi:10.1210/clinem/dgae329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。